Bristol-Myers Squibb Company Holdings Lowered by First American Bank

Following the transaction, the senior vice president now directly owns 55,637 shares in the company, valued at $3,187,443.73. Greatmark Investment Partners Inc who had been investing in Target Corp (Call) for a number of months, seems to be less bullish one the $32.19 billion market cap company. The James Investment Research Inc holds 18,898 shares with $1.66 million value, up from 2,252 last quarter. About 2.06 million shares traded. Delphi Automotive PLC (NYSE:DLPH) has risen 30.43% since September 27, 2016 and is uptrending. It has outperformed by 46.14% the S&P500.

Bb&T Securities Llc decreased Bristol Myers Squibb Co (BMY) stake by 37.98% reported in 2017Q2 SEC filing. On Friday, September 9 the stock rating was maintained by Barclays Capital with “Equal-Weight”. Jennison Ltd Com holds 0.12% of its portfolio in MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI) for 2.08M shares.

Bristol-Myers Squibb Company most recently reported earnings per share (EPS) of $0.74 for the June 2017 versus $0.69 in the same quarter a year ago, representing 7% growth.

Bristol-Myers Squibb Co (NYSE:BMY) had its target price raised by Jefferies Group LLC from $66.00 to $72.00 in a research report issued on Monday, September 11th, Marketbeat Ratings reports. It has underperformed by 39.89% the S&P500. Puzo Michael J has invested 0.35% in Bristol-Myers Squibb Co (NYSE:BMY). Therefore 32% are positive. Art Advsr Llc reported 40,790 shares. Jefferies Group now has a “Buy” rating and a $66.00 target price on the stock. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $64.20 target price for the company.in a report on Thursday, September 7th. Mcgowan Gp Asset Management Incorporated has 0.04% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 3,622 shares. The rating was maintained by Cowen & Co with “Hold” on Monday, July 10. The rating was maintained by Citigroup with “Buy” on Tuesday, September 20. Also, Director Theodore R. Samuels II purchased 12,000 shares of the firm’s stock in a transaction on Monday, February 27th.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The firm has “Hold” rating given on Wednesday, August 16 by Credit Suisse. Investors of record on Friday, October 6th will be given a dividend of $0.39 per share. Its down 0.65, from 1.77 in 2017Q1.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BMY. Sei Investments reported 665,573 shares stake. Bar Harbor Tru Ser invested in 0.28% or 9,640 shares. Family Mgmt stated it has 21,155 shares. Bnp Paribas Asset Mngmt Holdg has invested 0.35% in Bristol-Myers Squibb Co (NYSE:BMY). More interesting news about Bristol-Myers Squibb Co (NYSE:BMY) were released by: Seekingalpha.com and their article: “Bristol-Myers Squibb (BMY) Presents at Morgan Stanley Healthcare Conference …” published on September 12, 2017 as well as Marketwatch.com’s news article titled: “Bristol-Myers Squibb says late-stage cancer drug combination study met …” with publication date: September 07, 2017. Jpmorgan Chase & holds 22.54M shares. Pettyjohn Wood And White invested in 7,325 shares. BMO Capital Markets maintained Bristol-Myers Squibb Co (NYSE:BMY) rating on Friday, July 28. Ameriprise Financial has an ownership of 15,547,051 stocks of the biopharmaceutical firms shares valued at $845,504,000 following acquiring an extra 2,451,390 shares through out the previous quarter, Swiss National Bank boosted its stake in stocks of Bristol-Myers Squibb by 27.2% in the Q1. Shine Investment Advisory owns 815 shares for 0.02% of their portfolio. Joel Isaacson & Limited Liability Corp, a New York-based fund reported 12,986 shares. The original version of this piece of content can be read at https://weekherald.com/2017/09/27/bristol-myers-squibb-company-bmy-rating-reiterated-by-jefferies-group-llc.html. COPYRIGHT VIOLATION NOTICE: “Brokers Offer Predictions for Bristol-Myers Squibb Company’s FY2017 Earnings (BMY)” was first published by Equities Focus and is owned by of Equities Focus. The company has a market capitalization of $103.20 billion, a PE ratio of 22.98 and a beta of 1.18. After posting $0.74 EPS for the previous quarter, Bristol-Myers Squibb Co’s analysts now forecast 1.35 % EPS growth.

Since April 6, 2017, it had 0 insider purchases, and 1 insider sale for $1.81 million activity. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the stock. Therefore 50% are positive. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $63.74. Suntrust Robinson initiated the stock with “Buy” rating in Friday, April 7 report. As per Thursday, July 14, the company rating was maintained by Jefferies. 2,108,581 shares of the company traded hands. The firm earned “Buy” rating on Friday, April 29 by UBS. The rating was maintained by Deutsche Bank with “Hold” on Friday, October 28. As per Monday, September 18, the company rating was maintained by Keefe Bruyette & Woods.

More notable recent Target Corporation (NYSE:TGT) news were published by: Seekingalpha.com which released: “Target Goes For It” on September 19, 2017, also Investorplace.com with their article: “Trade of the Day: Target Corporation (TGT) Stock Is Waking Up” published on September 14, 2017, Seekingalpha.com published: “Target: Hold Your Breadth” on September 13, 2017.

Leave a Reply

Your email address will not be published. Required fields are marked *